Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Virginia

Peptide legality · Virginia · updated 2026-09-21

Are peptides legal in Virginia?

Gray area

In Virginia, peptides are legal only within the federal compounding framework, so brand-name GLP-1 medicines are fully legal by prescription while compounded and research peptides sit in a gray zone with rising enforcement.

Legal status overview

Virginia permits peptides only within the federal compounding framework, so brand-name GLP-1 medicines are legal by prescription while compounded and research peptides remain in a gray zone. The Virginia Board of Pharmacy, part of the Department of Health Professions, has not issued a peptide-specific rule and relies on the federal floor set by the FDA and sections 503A and 503B. Compounded semaglutide can still be prepared for a documented patient-specific clinical reason, but routine copies of Wegovy® (semaglutide) ended after the FDA declared the shortage resolved in February 2025. Research peptides such as BPC-157 and TB-500 are unscheduled but not FDA-approved, and state enforcement against high-volume telehealth weight-loss operations has increased. This is information, not medical or legal advice.

Key points

  • The Virginia Board of Pharmacy has not published a peptide-specific rule, so pharmacies follow the federal compounding floor set by the FDA and sections 503A and 503B. [3]
  • Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved and legal to prescribe in Virginia; only the compounded and research versions raise legality questions. [1]
  • After the FDA resolved the semaglutide shortage in February 2025, 503A pharmacies may compound semaglutide only for a documented patient-specific clinical reason such as an allergy or a needed dosage form. [6]
  • Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA. [1]
  • A telehealth provider must be licensed in the state where the patient is located, so a Virginia patient generally needs a Virginia-licensed prescriber. [6]
  • BPC-157 is not a controlled substance in Virginia and was removed from FDA Category 2 in April 2026, but it is not FDA-approved and not yet permitted for compounding pending final rulemaking. [4]
  • Enforcement against high-volume telehealth weight-loss shops and bulk-stocked compounded semaglutide has risen sharply nationally, a trend that reaches Virginia providers. [6]

Compound-by-compound status

BPC-157
Gray area
Not a controlled substance and not FDA-approved; removed from 503A Category 2 in April 2026 and recommended for 503A in July 2026, but not yet permitted for compounding pending final FDA rulemaking.
GLP-1 class: Wegovy® (semaglutide) and Zepbound® (tirzepatide)
Restricted
Branded products are FDA-approved and legal by prescription; compounded semaglutide and tirzepatide are not FDA-approved, are not a generic, and have not been evaluated by the FDA, and are permitted only for a documented patient-specific clinical need after the 2025 shortage resolution.
TB-500 (thymosin beta-4 fragment)
Restricted
Not FDA-approved and not on the permitted 503A bulk substances list; sold only as a research chemical and not authorized for human use.
Growth hormone / somatropin
Restricted
FDA-approved by prescription for defined indications; federal law (21 U.S.C. 333(e)) makes distribution for non-approved uses a crime, so access is tightly restricted.

Frequently asked questions

Is compounded semaglutide legal in Virginia?

It can be legal when a Virginia-licensed prescriber documents a patient-specific clinical reason and a licensed 503A pharmacy prepares it, but routine copies of Wegovy® (semaglutide) ended after the FDA resolved the shortage in February 2025. Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA.

Is BPC-157 legal in Virginia?

BPC-157 is not a controlled substance in Virginia, but it is not FDA-approved and is not currently permitted for pharmacy compounding, so it remains in a gray zone. Research-use-only products are not authorized for human use.

Does Virginia have a specific peptide statute?

No. The Virginia Board of Pharmacy relies on the federal framework under the FDA and sections 503A and 503B rather than a dedicated peptide rule.

Can I use telehealth for peptides in Virginia?

A telehealth prescriber generally must be licensed where the patient is located, so a Virginia patient needs a Virginia-licensed provider, and any compounded product must still meet federal limits.

Are brand-name GLP-1 drugs legal in Virginia?

Yes. Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved and legally prescribed; the uncertainty applies to compounded and research peptides.

General information based on the sourced research above, not legal advice. For a specific situation in Virginia, consult a licensed attorney familiar with pharmaceutical law.